Terns (TERN) Q2 Net Loss Narrows 16%

Terns Pharmaceuticals (TERN 6.00%), a clinical-stage biopharmaceutical company developing therapies for chronic myeloid leukemia (CML) and metabolic diseases, released its second quarter results on August 5, 2025. The most notable news was continued progress in its two lead clinical programs—TERN-701, a kinase inhibitor drug for CML, and TERN-601, an oral GLP-1 receptor agonist drug for obesity—while maintaining a robust cash balance. The GAAP net loss per share was $(0.26), slightly better than the expecte ...